UCB SA (UCB.BR) Stock Price & Overview
EBR:UCB • BE0003739530
Current stock price
The current stock price of UCB.BR is 246.6 EUR. Today UCB.BR is down by -2.14%. In the past month the price decreased by -11.02%. In the past year, price increased by 40.98%.
UCB.BR Key Statistics
- Market Cap
- 47.966B
- P/E
- 24.68
- Fwd P/E
- 23.98
- EPS (TTM)
- 9.99
- Dividend Yield
- 0.39%
UCB.BR Stock Performance
UCB.BR Stock Chart
UCB.BR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to UCB.BR. When comparing the yearly performance of all stocks, UCB.BR is one of the better performing stocks in the market, outperforming 87.09% of all stocks.
UCB.BR Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR. UCB.BR gets an excellent profitability rating and is at the same time showing great financial health properties.
UCB.BR Earnings
On February 26, 2026 UCB.BR reported an EPS of 6.46 and a revenue of 4.25B. The company beat EPS expectations (17.63% surprise) and beat revenue expectations (13.65% surprise).
UCB.BR Forecast & Estimates
27 analysts have analysed UCB.BR and the average price target is 282.94 EUR. This implies a price increase of 14.74% is expected in the next year compared to the current price of 246.6.
For the next year, analysts expect an EPS growth of 2.96% and a revenue growth 11.84% for UCB.BR
UCB.BR Groups
Sector & Classification
UCB.BR Financial Highlights
Over the last trailing twelve months UCB.BR reported a non-GAAP Earnings per Share(EPS) of 9.99. The EPS increased by 100.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.13% | ||
| ROA | 8.58% | ||
| ROE | 14.34% | ||
| Debt/Equity | 0.2 |
UCB.BR Ownership
UCB.BR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.18 | 188.754B | ||
| SNW | SANOFI | 9.21 | 188.634B | ||
| 1SAN | SANOFI | 8.95 | 183.223B | ||
| UNC | UCB SA | 24.47 | 48.958B | ||
| 1MRK | MERCK KGAA | 13.45 | 48.348B | ||
| MRK | MERCK KGAA | 12.59 | 46.674B | ||
| 1BAYN | BAYER AG-REG | 8.44 | 38.825B | ||
| BAYN | BAYER AG-REG | 8.2 | 37.789B | ||
| IPN | IPSEN | 12.26 | 12.756B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.414B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 15.59 | 9.302B | ||
| VIRP | VIRBAC SA | 16.35 | 2.974B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Brussels Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find more growth stocks the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About UCB.BR
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Company Info
IPO: 1987-01-02
UCB SA
Allee de la Recherche, 60
Anderlecht BRUXELLES-CAPITALE BE
Employees: 9215
Phone: 3225599999
UCB SA / UCB.BR FAQ
What does UCB do?
UCB SA engages in the research and development of biopharmaceuticals products. The company is headquartered in Anderlecht, Bruxelles-Capitale. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Can you provide the latest stock price for UCB SA?
The current stock price of UCB.BR is 246.6 EUR. The price decreased by -2.14% in the last trading session.
What is the dividend status of UCB SA?
UCB SA (UCB.BR) has a dividend yield of 0.39%. The yearly dividend amount is currently 1.39.
What is the ChartMill rating of UCB SA stock?
UCB.BR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the PE ratio for UCB stock?
The PE ratio for UCB SA (UCB.BR) is 24.68. This is based on the reported non-GAAP earnings per share of 9.99 and the current share price of 246.6 EUR.
What is UCB SA worth?
UCB SA (UCB.BR) has a market capitalization of 47.97B EUR. This makes UCB.BR a Large Cap stock.